Latest Breaking News On - Athyrium capital management - Page 8 : comparemela.com

Biora Therapeutics Announces $9 75 Million Direct Offering

07.11.2022 - SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) - Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the . Seite 1

New yorkUnited statesExchange commissionHc wainwright coConvertible senior notesAthyrium capital management

Biodrain Medical (BIOR) Prices 32 5M Share Direct Offeirng at $0 30/sh

Biodrain Medical (BIOR) Prices 32 5M Share Direct Offeirng at $0 30/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesExchange commissionBiora therapeutics incHc wainwright coConvertible senior notesAthyrium capital management

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

Investegate announcements from Basilea Pharmaceutica AG, Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

Basel stadtBasel allschwilNils schrAdesh kaulBasilea pharmaceutica international ltdHead of corporate communications investor relationsSwiss exchangeBasilea pharmaceutica ltdPharmaceutica ltdAthyrium capital managementChief financial officerCorporate communicationsPharmaceutica international ltdInvestegate announcementsInvestegate company announcementsBasilea pharmaceutica ag

Basilea Pharmaceutica AG: Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

Basel/Allschwil, Switzerland, September 21, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial

Basel stadtBasel allschwilNils schrAdesh kaulBasilea pharmaceutica international ltdHead of corporate communications investor relationsSwiss exchangeBasilea pharmaceutica ltdPharmaceutica ltdAthyrium capital managementChief financial officerCorporate communicationsPharmaceutica international ltd

Basilea announces CHF 75 million senior secured loan

Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 07, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage.

Basel stadtBasel allschwilLaurentd hermouetNils schrAdesh kaulBasilea pharmaceutica international ltdHead of corporate communications investor relationsSwiss exchangeBasilea pharmaceutica ltdPharmaceutica ltdAthyrium capital managementChief financial officerCorporate communicationsPharmaceutica international ltdSwiss stock exchange bslnBasilea pharmaceutica ag